New version of cancer drug Keytruda is 'easier' but poised to keep price high, N.Y. Times reports

Although drug manufacturer Merck says its new injected version of Keytruda will be cheaper and easier,  prices will probably stay high.

That conclusion was drawn in a recent story by Rebecca Robbins in The New York Times.

A subhead in the online article, which labels the original drug a "blockbuster," says the new version, which was given Federal Drug Administration last Friday, "stands to slow the adoption of cheaper competitors and increase costs by billions of dollars."

Dr. Benjamin Rome

The new version, Keytruda Qlex, is given via a shot under the skin while the original therapy is given through tubes as an intravenous infusion, the piece notes.

Merck, whose original patent is scheduled to run out in 2028, "followed a well-worn playbook," Robbins' story says, explaining that the corporation's "strategy is known as a product 'hop.' A company rides out its monopoly on the original drug, and then, a few years before competition reaches the market, the drugmaker 'hops' to a new version that remains protected by patents."

The Times article quotes Dr. Benjamin Rome, health policy researcher at Brigham and Women's Hospital in Boston, as saying that "we probably don't want to be paying so much much for these small additions on the tail end of a product that has already made billions of dollars."

Robbins' piece also reports that Democrat Sen. Elizabeth Warren of Massachusetts and Independent Sen. Bernie Sanders of Vermont "have accused Merck of abusing the patent system with the new Keytruda shot."

Dr. Marjorie Green, a  Merck exec, has called the new version "a meaningful advance," according to the Times.

Keytruda, which has been given 2.9 million patients and is "approved to treat 18 types of cancer, including of the skin, lung, breast, and colon," helped former President Jimmy Carter "extend his life by nearly a decade," the story adds. 

The drug, which accounts for nearly half of Merck's revenue, has generated $146 billion  in sales for the business. 

The new kinds of injections "have proved popular with hospitals," the story says, "because they free up infusion chairs for patients receiving chemotherapy and allow them to treat more patients." In a clinical study funded by Merck, the piece continues, "the Keytruda shot, injected into the stomach area or thigh, took about two minutes to administer compared with 30 minutes for the original infusion."

More information on drugs can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details.

Marathon and extreme runners much more likely to have pre-cancerous colon polyps, study says

A new study conducted by a Virginia doctor shows that comparatively young marathon and ultra-marathon runners are more apt to have pre-cancerous colon growths.

Dr. Timothy Cannon

The study by oncologist Timothy Cannon, who tested colonoscopies at the Inova Schar Cancer Institute in Fairfax, Va., on 100 volunteers aged 35 to 50, was showcased yesterday in a story by Roni Caryn Rabin in The New York Times.

"The results," the article says, "were staggering. Almost half the participants had polyps, and 15 percent had advanced adenomas likely to become cancerous."

The new study, the piece continued, "comes amid heightened concerns about a rise in colon and rectal cancer rates among adults under 50, a population that  historically has had a low risk of cancer."

Cannon, who ran the New York City marathon in 2010, is quoted believing that "after what I've seen from my patients and what we've found here, that extreme exercise may increase the risk."

As for continuing to run, he added that "you never want to give people an excuse not to exercise, because by and large we have bigger problems from people not exercising enough.

More information on what can cause the disease can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details.

3 out of 5 liver cancers are preventable, new study discovers; cases could double in 25 years

Sixty percent of the 700,000 people who die each year from liver cancer could be prevented, reports a new study published in the journal Lancet.

That comprehensive research, according to a recent story by Nina Agrawal in The New York Times, finds that "prevention could be accomplished by addressing the disease's major causes: hepatitis B, hepatitis C, alcohol-associated liver disease, and liver disease linked to metabolic risk factors like obesity."

Dr. Brian P. Lee

The Times article quotes Dr. Brian P. Lee, an associate professor of medicine at the Keck School of Medicine at the University of Southern California, who was not involved in the study, to the effect that "liver cancer is common, it causes immense suffering and death, and the saddest part for me as a physician is that most of the cases are preventable."

Liver cancer is the sixth most common cancer and the third leading cause of death each year from cancer. There are nearly 900,000 new annual cases globally, Agrawal's piece indicates.

The story also quotes Dr. Ahmed Kaseb, a professor of gastrointestinal medical oncology at the University of University of Texas MD Anderson Cancer Center, who also wasn't associated with the study, as suggesting that the threat of liver cancer from heavy alcohol use and metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease, "has been under-recognized and underestimated." 

Dr., Hashem El-Serag, chair of the department of medicine at Baylor College of Medicine in Texas and one of the authors of the new study, maintains that a vast majority of liver cancers arise in people with cirrhosis, advanced and largely irreversible scarring of the liver, which is definitively linked to heavy  alcohol consumption.

More information on the variety of cancers can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website at https://woodyweingarten.com for details.

Face of lung cancer — once older men with a history of smoking — has changed significantly

Many lung cancers are now found in non-smokers, and scientists want to know why.

According to the headline of a story by Nina Agrawal and Allison Jiang in The New York Times early this week, "the face of lung cancer — once older men with a history of smoking — has changed." Significantly.

Lung cancer is the deadliest cancer in the United States, notes the article that then goes on to say that "the disease's incidence and death rates have dropped over the last few decades, thanks largely to a decline in cigarette use, but lung cancers unrelated to smoking have persisted."

Worldwide, "roughly 10 to 25 percent of lung cancers now occur in people who have never smoked," the piece continues, "Among certain groups of Asian and Asian American women, that share is estimated to be 50 per cent or more."

Dr. Maria Teresa Landi

The thinking used to be that smoking was "almost the only cause of lung cancer," the story quotes Dr. Maria Teresa Landi, a senior investigator at the National Cancer Institute, which is part of the National Institutes of Health. 

Landi is studying "the role that environmental exposure, genetic mutations, or other risk factors might play. She and other researchers "have already found some early hints, including a clear link to air pollution," Agrawal and Jiang's article states.

The piece also quotes Dr. Heather Wakelee, chief of oncology  at the Stanford University School of Medicine, to the effect that "we all still think about the Marlboro man as whaat lung cancer looks like." 

In many cases, however, that's no longer the case. "We're just baffled as to why," Wakelee adds.

One large study led by Landi and colleagues at the University of California, San Diego, the Times story reports, "is looking at the mutational signatures, or patterns of mutations across the cancer genomes, of 871 non-smokers with lung cancer from around the world."

Their latest findings from the study, dubbed Sherlock Lung and published in Nature this month, "showed that certain mutations, or changes to DNA, were much more common in people who lived in areas with high amounts of air pollution —  for example, Hong Kong, Taiwan, and Uzbekistan," the article says.

More information on the multiple kinds of cancer can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten, aimed at caregivers. I am, in fact, hard at work on a second edition. 

My other books are Mystery Dates — How to keep the sizzle in our relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my blog at https://woodyweingarten.com for more info on them.

Cutting-edge cancer therapy offers hope for cure for patients with lupus, New York Times reports

A relatively new treatment called CAR T-cell therapy appears to stop lupus in its tracks, according to a recent story by Nina Agrawal in The New York Times.

Her article explains that the treatment is "a kind of 'living drug' that modifies patients' immune cells to help them attack misbehaving ones."

Agrawal's piece quotes Dr. Lisa Sammaritano, a rheumatologist at the Hospital for Special Surgery — Weill Cornell Medicine and the lead author of a set of recently updated guidelines for lupus treatment, as saying, "It's really promising, and honestly the first therapy that we've talked about as a cure. [Until now] we haven't had a cure — we've had control." 

She adds a major caveat, to the effect that she's "hoping that it's a common future therapy, but we're not at the point yet where we can say that with confidence."

CAR T-cell therapy, the Times story notes, is one that "must be personalized to each patient [and therefore] is extraordinarily expensive." One-time costs approach half a million dollars or more.

Symptoms of lupus typically appear between the ages of 15 and 44, with 90 percent of the 3 million patients worldwide being women.

Dr. Meghan Sise

Half of lupus patients, the Agrawal story says, "have inflammation in their kidneys, a condition known as lupus nephritis. Between 10 and 30 percent of these patients will eventually need dialysis or a kidney transplant transplant, [says] Dr. Meghan Sise, the director of onconephrology at Massachusetts General Hospital."

Dr. April Barnado

The disease can cause joint pain, rashes, severe fatigue, and inflammation in organs, the story quotes Dr.. April Barnado, rheumatologist and assistant professor of medicine at Vanderbilt University Medical Center, as saying.

It often strikes, she adds, "at a time when women are raising families, or they're caregiving, or they're trying to get promoted at work. They wake up and feel like they have the flu or a viral infection a few days a week every week. That's pretty debilitating."

Lupus, formally labeled systemic lupus erythematosus, according to the article "is an autoimmune condition in which he body develops antibodies against its own DNA and other cellular material.  The name derives fro m the Latin for 'wolf,' because the skin lesions the disease sometimes causes were once thought to resemble wolf bites, some say." 

More information on treatments and drugs can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my blog at https://woodyweingarten.com for even more info.

Camera examination of ancient skull shows that Egyptians tried to remove cancer 4,500 years ago

By examining an Egyptian skull from 4,500 years ago, an archeologist and his team apparently have "changed the previously understood timeline of when humans may have tried to treat cancer." 

A story by Ben Brasch in editions of The Washington Post a while back quotes archeologist Edgard Camarós, PhD professor at the University of Santiago de Compostela in Spain, as saying "it was clear that we were looking at a milestone in the history of medicine. That was one of those eureka moments." 

Camarós and his team maintain that they've "found proof that moves forward our under landing of when humans treat to treat cancer by 1,000 years."

Edgard Camarós

The team recently published a report in the Frontiers in Medicine journal explaining how they used new camera-and-screen technology and how the markings they found indicate that ancient scientists were trying to remove cancer from a skull.

According to the Centers for Disease Control and Prevention, cancer was the second-leading cause of death in the United States in 2022.

More information linking research and diseases can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten, aimed at caregivers.

Immunotherapy in clinical trial takes one-third of patients from hopelessness to a potential cure

Despite multiple myeloma having been considered incurable, a third of patients in a clinical trial have lived without detectable cancer for five years.

Patients in the trial conducted by Johnson & Johnson researchers had been facing "certain, and extremely painful, death within a year," according to a story by Gina Kolata in yesterday's editions of The New York Times.

But after five years, the immunotherapy developed by Legend Biotech, a company founded in China, seems to have made the cancer disappear in a third of the patients — "a result never before seen in this disease."

Dr. Norman Sharpless

"In my 30 years in oncology, we haven't talked about curing myeloma," the Times quoted Dr. Norman Sharpless," professor of cancer policy and innovation at the University of North Carolina School of Medicine and a former director of the National Cancer Institute. "This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable."

The study by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech, was published in The Journal of Clinical Oncology and reported yesterday at the annual conference of the American Society of Clinical Oncology.

"The Legend immunotherapy is a type known as CAR-T," Kolata's article explains. "It is delivered as an infusion of the patient’s own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionized prospects for patients with other types of blood cancer, like leukemia."

Treatments for multiple myeloma are extremely costly. They can run more than $100,000 —  "hideously expensive," according to Dr. Carl June of the University of Pennsylvania. Total cost over the years can be millions of dollars, usually paid by insurers, "and it doesn't even cure you," he told the Times.

Thirty-six thousand Americans each year develop the deadly blood disease, which eats away at bones so it looks as though holes have been punched out in them, elaborates June. Bones can collapse. 

"It's a horrible, horrible death," says June.

More information on clinical trials can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Find out more on my blog, https://woodyweingarten.com.

Biden and his allies are 'very optimistic' about his ability to beat metastasized prostate cancer

Former President Joe Biden

Former President Joe Biden and those around him appear to be sanguine about his being able to whip his metastasized prostate cancer — even though there is no cure.

Looking forward to his recovery, he specifically told reporters last week that "we're going to be able to beat this."

According to an online story by Sebastian Murdock in the HuffPost, he also said, "The prognosis is good. We're working on everything. It's moving along, and I feel good. All the folks are very optimistic."

Earlier last month the 82-year-old was diagnosed with the Stage 4 cancer that had metastasized to the bone. Biden's office admitted it was "a more aggressive form of the disease."

In a chat with reporters at his home, Biden said, "The expectation is we're going to be able to beat this...It's not in any organ, my bones are strong."

The New York Times earlier had quoted Dr. Judd Moul, a prostate cancer expect at Duke University, as saying that men whose prostate cancer had metastasized "can live five, seven, 10 more years." 

He noted that "survival rates have almost tripled in the last decade."

More information on metastasis can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten aimed at male caregivers. My other books are MysteryDates — How to keep the sizzle in your relationship; The Roving I, a compilation of 70 of my newspaper columns; and Grampy and His Fairyzona Playmates, a whimsical fantasy intended for 6- to 10-year-olds that I co-authored with my then 8-year-old granddaughter. Check out my website, https://woodyweingarten.com/.